Two NEJM Papers Evaluate Imetelstat in Myelofibrosis and Essential Thrombocythemia

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Two separate papers published in the New England Journal of Medicine showed that imetelstat demonstrated disease-modifying activities in phase II studies of myelofibrosis and essential thrombocythemia.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login